Hypertension is a chronic disease. In all chronic diseases treatment adherence is important to prevent adverse consequences. No data are available in the literature on the adherence of rilmenidine therapy.Objective:
Our aim was to investigate the newly initiated one year persistence of ARBs, ACE-inhibitors compare to rilmenidine in hypertension.Design and method:
Using the database of the National Health Insurance of Hungary, we choose patients who were prescribed ACE-inhibitors, ARBs and rilmenidine for the first time in the indication of hypertension (ICD: I10H0) between the 1st of October 2012 and the 30th of September 2013. These patients received no antihypertensive therapy with similar active substances during the previous 1 year. In the three groups were investigated the refill of receipts monthly. All patients were followed for 14 month. Patients died were excluded from analysis. 60 days of drug discontinuation were tolerated as a Grace period. We evaluated the proportion of persistent patients by monthly. Patients taking ARBs were regarded as the reference group.Results:
During the study period 164,213 took ARBs, 185,239 ACE-inhibitorsResults:
and 37,217 rilmenidine. The 1 year persistence of antihypertensive therapy was 37% in patients with ARBs, 31% in patients with rilmenidine and 27% in patients with ACE-inhibitors. The hazard ratio of discontinuing rilmenidine 1.25 (CI, 1.24–1.27, p < 0.001), and ACE-inhibitors 1,29 (CI, 1.28–1.30, p < 0.001) compared to ARBs as the reference.Conclusions:
One year persistence of rilmenidine was found between ARBs and ACEinhibitors.